Neang S. Ly
YOU?
Author Swipe
View article: Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer Open
These results support the dosing strategy implemented in COSMIC-311 and the BSA-based label recommendations for adolescents. The cabozantinib dose should be reduced to manage adverse events as indicated.
View article: Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma Open
View article: 548: Evaluation of elexacaftor/tezacaftor/ivacaftor on pulmonary function in cystic fibrosis patients
548: Evaluation of elexacaftor/tezacaftor/ivacaftor on pulmonary function in cystic fibrosis patients Open
View article: 271: Loss of control, shifts in illness identity, and perceived vulnerability underlie traumatic illness–related experiences in patients with cystic fibrosis
271: Loss of control, shifts in illness identity, and perceived vulnerability underlie traumatic illness–related experiences in patients with cystic fibrosis Open
View article: Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii
Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii Open
The prevalence of heteroresistant Acinetobacter baumannii is increasing. Infections due to these resistant pathogens pose a global treatment challenge. Here, the pharmacodynamic activities of polymyxin B (PMB) (2–20 mg/L) and tigecycline (…
View article: Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies Open
Polymyxin B is being increasingly utilized as a last resort against resistant Gram-negative bacteria. We examined the pharmacodynamics of novel dosing strategies for polymyxin B combinations to maximize efficacy and minimize the emergence …
View article: Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses Open
View article: Influence of <i>rhlR</i> and <i>lasR</i> on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin
Influence of <i>rhlR</i> and <i>lasR</i> on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin Open
The impact of quorum sensing on polymyxin and azithromycin pharmacodynamics was assessed in Pseudomonas aeruginosa PAO1 and an isogenic rhlR / lasR double knockout. For polymyxin B, greater killing against the rhlR / lasR knockout than aga…
View article: Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes
Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes Open
View article: Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery
Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery Open
Ertapenem provides broad-spectrum activity against many pathogens, and its use is relevant for the prophylaxis and treatment of infections in morbidly obese patients undergoing surgery. However, its pharmacokinetics and tissue penetration …
View article: Polymyxin B in combination with doripenem against heteroresistant <i>Acinetobacter baumannii</i> : pharmacodynamics of new dosing strategies
Polymyxin B in combination with doripenem against heteroresistant <i>Acinetobacter baumannii</i> : pharmacodynamics of new dosing strategies Open
Early aggressive dosing regimens for polymyxin combinations demonstrate promise for treatment of heteroresistant A. baumannii infections.
View article: Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii
Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii Open
View article: Accuracy of forced oscillation technique to assess lung function in geriatric COPD population
Accuracy of forced oscillation technique to assess lung function in geriatric COPD population Open
Hoi Nam Tse,1 Cee Zhung Steven Tseng,1 King Ying Wong,2 Kwok Sang Yee,2 Lai Yun Ng1 1Medical and Geriatric Department, Respiratory Unit, Kwong Wah Hospital, 2Department of Tuberculosis and Chest Unit, Wong Tai Sin Hospital, Hong Kong, Peop…
View article: Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa
Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa Open
Development of spontaneous mutations in Pseudomonas aeruginosa has been associated with antibiotic failure, leading to high rates of morbidity and mortality. Our objective was to evaluate the pharmacodynamics of polymyxin B combinations ag…
View article: Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators
Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators Open
The interplay between polymyxin B pharmacodynamics and pathogenicity was examined in Pseudomonas aeruginosa PAO1 and isogenic DNA repair-deficient mutators ( mutM and mutS strains). Against mutS mutators, polymyxin B initial killing was co…
View article: Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i>: profiling the time course of synergistic killing and prevention of resistance
Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i>: profiling the time course of synergistic killing and prevention of resistance Open
Objectives Colistin is an ‘old’ drug, which is being increasingly utilized due to limited therapeutic options. However, resistance emergence during monotherapy is concerning. Here, our objective was to optimize colistin combinations agains…
View article: Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling
Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling Open
Bacterial resistance is among the most serious threats to human health globally, and many bacterial isolates have emerged that are resistant to all antibiotics in monotherapy. Aminoglycosides are often used in combination therapies against…